FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2513053989> ?p ?o ?g. }

• W2513053989 endingPage "5749" @default.
• W2513053989 startingPage "5749" @default.
• W2513053989 abstract "Abstract We retrospectively compared the impact of treatments based on thalidomide, bortezomib or tranditional regimen (VAD) on renal function recovery in a consecutive, unselected population of newly diagnosed myeloma patients presenting with renal failure. Between May 2005 and February 2014, 130 (24.3%) patients with newly diagnosed multiple myeloma and RI were treated upfront with VAD or a novel agent containing regimen and all received a similar supportive care in our single center. A complete recovery of renal function(renal complete response )was observed in 56.1% of patients treated with bortezomib, in 38.9% with thalidomide and in 28.6% with VAD (P=0.033), a significant improvement of renal function (≥renalPR (renal partial response)) was observed in 63.6% of patients treated with bortezomib, in 66.1% with thalidomide and in 42.9% with VAD (P=0.162). There has a significantly difference in the rates and quality of renal response among patients with different quality of myeloma response: renal CR rates for patients who achieved ≥VGPR, PR, MR or NR were 63.1% vs 46.8% vs 35.7% vs 25.8%, P<0.05, respectively. eGFR ≥30 ml/min and myeloma response higher than PR were independently associated with a higher probability of major renal response in the multivariate analysis. The median follow-up for all patients was 36.5 months and the median survival was 74 months. The median survival for patients of groups B,T and VAD was79 months,71 months and 39 months, respectively (P=0.007). Patients died within the first 2 months from initiation of therapy and the corresponding frequencies in groups B, T and VAD were 0%, 2.8% and 17.9%, respectively (P<0.05). In multivariate analyses on survival, myeloma response higher than PR and new agents-based therapy are identified independent prognostic factors. For newly diagnosed myeloma patients with RI, bortezomib or thalidomide based regimen should be selected promptly to achieve rapid effective myeloma rate and high rates of renal recovery. Disclosures No relevant conflicts of interest to declare." @default.
• W2513053989 created "2016-09-16" @default.
• W2513053989 creator A5011029344 @default.
• W2513053989 creator A5013530856 @default.
• W2513053989 creator A5057603195 @default.
• W2513053989 date "2014-12-06" @default.
• W2513053989 modified "2023-09-27" @default.
• W2513053989 title "Reversibility of Renal Insufficiency in Patients with Newly Diagnosed Multiple Myeloma and the Role of different induction Regimens" @default.
• W2513053989 doi "https://doi.org/10.1182/blood.v124.21.5749.5749" @default.
• W2513053989 hasPublicationYear "2014" @default.
• W2513053989 type Work @default.
• W2513053989 sameAs 2513053989 @default.
• W2513053989 citedByCount "0" @default.
• W2513053989 crossrefType "journal-article" @default.
• W2513053989 hasAuthorship W2513053989A5011029344 @default.
• W2513053989 hasAuthorship W2513053989A5013530856 @default.
• W2513053989 hasAuthorship W2513053989A5057603195 @default.
• W2513053989 hasConcept C126322002 @default.
• W2513053989 hasConcept C126894567 @default.
• W2513053989 hasConcept C141071460 @default.
• W2513053989 hasConcept C159641895 @default.
• W2513053989 hasConcept C2776063141 @default.
• W2513053989 hasConcept C2776364478 @default.
• W2513053989 hasConcept C2777478702 @default.
• W2513053989 hasConcept C2779609412 @default.
• W2513053989 hasConcept C2781413609 @default.
• W2513053989 hasConcept C2908647359 @default.
• W2513053989 hasConcept C71924100 @default.
• W2513053989 hasConcept C90924648 @default.
• W2513053989 hasConcept C99454951 @default.
• W2513053989 hasConceptScore W2513053989C126322002 @default.
• W2513053989 hasConceptScore W2513053989C126894567 @default.
• W2513053989 hasConceptScore W2513053989C141071460 @default.
• W2513053989 hasConceptScore W2513053989C159641895 @default.
• W2513053989 hasConceptScore W2513053989C2776063141 @default.
• W2513053989 hasConceptScore W2513053989C2776364478 @default.
• W2513053989 hasConceptScore W2513053989C2777478702 @default.
• W2513053989 hasConceptScore W2513053989C2779609412 @default.
• W2513053989 hasConceptScore W2513053989C2781413609 @default.
• W2513053989 hasConceptScore W2513053989C2908647359 @default.
• W2513053989 hasConceptScore W2513053989C71924100 @default.
• W2513053989 hasConceptScore W2513053989C90924648 @default.
• W2513053989 hasConceptScore W2513053989C99454951 @default.
• W2513053989 hasIssue "21" @default.
• W2513053989 hasLocation W25130539891 @default.
• W2513053989 hasOpenAccess W2513053989 @default.
• W2513053989 hasPrimaryLocation W25130539891 @default.
• W2513053989 hasRelatedWork W1972519999 @default.
• W2513053989 hasRelatedWork W1999964913 @default.
• W2513053989 hasRelatedWork W2004610773 @default.
• W2513053989 hasRelatedWork W2009883886 @default.
• W2513053989 hasRelatedWork W2013163224 @default.
• W2513053989 hasRelatedWork W2173932373 @default.
• W2513053989 hasRelatedWork W2988379501 @default.
• W2513053989 hasRelatedWork W3032328885 @default.
• W2513053989 hasRelatedWork W3127479238 @default.
• W2513053989 hasRelatedWork W4244042359 @default.
• W2513053989 hasVolume "124" @default.
• W2513053989 isParatext "false" @default.
• W2513053989 isRetracted "false" @default.
• W2513053989 magId "2513053989" @default.
• W2513053989 workType "article" @default.